206 related articles for article (PubMed ID: 7786397)
1. Synthesis and biological evaluation of basic side chain derivatives of Analog II as pure antiestrogens and antitumor agents.
Magarian RA; Avor KS; Overacre LB; Kunchandy J; Paxton TR
Anticancer Drug Des; 1995 Jun; 10(4):311-31. PubMed ID: 7786397
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of a series of gem-dichlorocyclopropanes as antitumor agents.
Griffin MT; Magarian RA; Jain P; Pento JT; Mousissian GK; Graves DC
Anticancer Drug Des; 1992 Feb; 7(1):49-66. PubMed ID: 1543527
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
Murphy CS; Parker CJ; McCague R; Jordan VC
Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
[TBL] [Abstract][Full Text] [Related]
4. Guide-lines in the design of new antiestrogens and cytotoxic-linked estrogens for the treatment of breast cancer.
Leclercq G; Devleeschouwer N; Heuson JC
J Steroid Biochem; 1983 Jul; 19(1A):75-85. PubMed ID: 6887875
[TBL] [Abstract][Full Text] [Related]
5. Antiestrogenic effects of Z-1, 1-dichloro-2,3 diphenyl-2-(4-methoxyphenyl)cyclopropane(5a) on human breast cancer cells in culture.
Jain PT; Pento JT; Magarian RA
Anticancer Res; 1992; 12(3):585-90. PubMed ID: 1622114
[TBL] [Abstract][Full Text] [Related]
6. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
Miller MA; Lippman ME; Katzenellenbogen BS
Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
[TBL] [Abstract][Full Text] [Related]
7. Cellular targets of the anti-breast cancer agent Z-1,1-dichloro-2,3-diphenylcyclopropane: type II estrogen binding sites and tubulin.
ter Haar E; Hamel E; Balachandran R; Day BW
Anticancer Res; 1997; 17(3C):1861-9. PubMed ID: 9216636
[TBL] [Abstract][Full Text] [Related]
8. Cytostatic and cytotoxic action of Z-1, 1-dichloro-2,3-diphenylcyclopropane in three human breast cancer cell lines.
ter Haar E; Day BW
Anticancer Res; 1996; 16(3A):1107-15. PubMed ID: 8702221
[TBL] [Abstract][Full Text] [Related]
9. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth.
Coezy E; Borgna JL; Rochefort H
Cancer Res; 1982 Jan; 42(1):317-23. PubMed ID: 7053859
[TBL] [Abstract][Full Text] [Related]
11. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
[TBL] [Abstract][Full Text] [Related]
12. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].
Bachmann-Moisson N; Barberi-Heyob M; Merlin JL; Ledrich ML; Batt AM; Guillemin F
Bull Cancer; 1996 Oct; 83(10):808-15. PubMed ID: 8952630
[TBL] [Abstract][Full Text] [Related]
13. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
[TBL] [Abstract][Full Text] [Related]
14. Non-steroid receptor-mediated antiproliferative activity of styrylpyrone derivative in human breast cancer cell lines.
Pihie AH; Stanslas J; Din LB
Anticancer Res; 1998; 18(3A):1739-43. PubMed ID: 9673398
[TBL] [Abstract][Full Text] [Related]
15. Steroidal affinity labels of the estrogen receptor. 3. Estradiol 11 beta-n-alkyl derivatives bearing a terminal electrophilic group: antiestrogenic and cytotoxic properties.
Lobaccaro C; Pons JF; Duchesne MJ; Auzou G; Pons M; Nique F; Teutsch G; Borgna JL
J Med Chem; 1997 Jul; 40(14):2217-27. PubMed ID: 9216841
[TBL] [Abstract][Full Text] [Related]
16. The effect of droloxifene on the insulin-like growth factor-I-stimulated growth of breast cancer cells.
Kawamura I; Lacey E; Mizota T; Tsujimoto S; Nishigaki F; Manda T; Shimomura K
Anticancer Res; 1994; 14(2A):427-31. PubMed ID: 8017842
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationships of ferrocenyl tamoxifen derivatives with modified side chains.
Nguyen A; Top S; Pigeon P; Vessières A; Hillard EA; Plamont MA; Huché M; Rigamonti C; Jaouen G
Chemistry; 2009; 15(3):684-96. PubMed ID: 19053086
[TBL] [Abstract][Full Text] [Related]
18. Carboxylic acid analogues of tamoxifen: (Z)-2-[p-(1, 2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine. Estrogen receptor affinity and estrogen antagonist effects in MCF-7 cells.
Kraft KS; Ruenitz PC; Bartlett MG
J Med Chem; 1999 Aug; 42(16):3126-33. PubMed ID: 10447957
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of tamoxifen and analogs with nonbasic side chains on cell proliferation in vitro.
Murphy LC; Sutherland RL
Endocrinology; 1985 Mar; 116(3):1071-8. PubMed ID: 3971898
[TBL] [Abstract][Full Text] [Related]
20. Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro.
Jordan VC; Lieberman ME; Cormier E; Koch R; Bagley JR; Ruenitz PC
Mol Pharmacol; 1984 Sep; 26(2):272-8. PubMed ID: 6482874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
